Boreal Genomics announces the appointment of Nitin Sood to CEO

Boreal Genomics announces the appointment of Nitin Sood to CEO

 Vancouver, BC, Canada - June 29, 2011

Boreal Genomics, the developer of the SCODA nucleic acid purification and sequence specific target enrichment technology, announced today that Nitin Sood has been appointed Chief Executive Officer and member of the company's Board of Directors.  Sood joins founder and Chief Scientific Officer, Dr. Andre Marziali, who will continue serving as a Board member and on the company Executive Team.

Sood joins Boreal from Agilent Technologies, Life Science Group, where he most recently served as General Manager in charge of the Automation business.  In his 5 years at Agilent, he led the growth of business units in both Automation (Santa Clara, CA) and Electrophoresis (Waldbronn, Germany) demonstrating successful launch of new products, increases in revenue and profitability, and development of emerging markets.  Sood brings more than 15 years of experience in product development and commercialization, which includes senior management experience at Applied Biosystems. Sood holds master's degrees in computer science and molecular biology. 

"We are delighted to have Nitin join the Boreal team as our new CEO. As Boreal has grown beyond the research stage to product commercialization and distribution, we feel fortunate to have attracted someone of Nitin's caliber to drive Boreal toward commercial success. Nitin's outstanding successes at Agilent, his proven leadership skills, and extensive experience in instrument commercialization will power the next stages of growth at Boreal as we move toward new markets in forensics and clinical diagnostics," said Marziali.  We are very excited about the innovation and application progress Boreal has made to date. Coupling this remarkable progress and the Boreal team with first tier commercial leadership in the person of Nitin Sood, is a powerful combination and one that will lead Boreal to important commercial successes," said Keith Crandell, Co-founder and Managing Director, ARCH Venture Partners.

Suggested Articles

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.